Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, has broadened its footprint in the United States by opening a new office in Cambridge, Massachusetts. This strategic move places IAG’s operations and business development teams in closer proximity to biotechnology and pharmaceutical companies, facilitating stronger partnerships and enhanced local support for clinical trials throughout the region.
The Cambridge office will bolster IAG’s initiatives across a wide range of therapeutic areas, such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. By establishing a presence in the Boston area, IAG aims to collaborate more effectively with sponsors and contract research organizations involved in Phase I–III clinical trials and imaging-intensive development programs. The expansion is also set to generate local employment opportunities, with plans to hire in clinical imaging operations, data science, regulatory support, and business development expected over the next 12 to 24 months.
In addition to fostering closer collaboration with local biotech firms, pharmaceutical organizations, academic institutions, and clinical research centers, the new office will support IAG’s comprehensive imaging services. These services include clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery, all aimed at enhancing the efficiency and accuracy of clinical research efforts.
Globally, IAG conducts clinical trials across North America, Europe, and the Asia-Pacific region, partnering with pharmaceutical, biotechnology, and medtech companies, along with CROs, to manage multi-center studies. The company’s global operations are structured to ensure standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across international trials, thus maintaining high-quality research outputs.
Founded in 2007 and headquartered in London, Image Analysis Group functions as an imaging Clinical Research Organization (iCRO). The company supports pharmaceutical, biotechnology, and medical technology sectors with imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, reinforcing their commitment to advancing imaging in clinical research.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.